HK-RT

Original price was: $49.99.Current price is: $28.99.

HK-RT is a catalog code for a triple-agonist incretin analog, available in 10 mg and 30 mg vials for laboratory research. Review the corresponding lot documentation before use. Not for human or veterinary use.

Amount

Clear

Category: Research Compounds

Guaranteed Safe Checkout

Coming soon. This compound is listed while photography and lot documentation are prepared. It cannot be purchased yet.

BEFORE YOU ORDER

Review the documentation.

Check the current report status and match documentation to your vial’s lot.

Open documentation hub →

RESEARCH COMPOUND

What is HK-RT?

HK-RT is Heavy Kingdom’s catalog code for a synthetic triple-agonist incretin analog (LY3437943). In laboratory research it is used to examine simultaneous activity at GLP-1, GIP, and glucagon receptors.

This listing is for laboratory research only. It is not a medicine, not for human or veterinary use, and this page does not provide dosing or administration guidance.

Mechanism of action

HK-RT is studied for concurrent engagement of three receptor targets used in metabolic signaling research:

GLP-1R — glucagon-like peptide-1 receptor
GIPR — glucose-dependent insulinotropic polypeptide receptor
GCGR — glucagon receptor

The combined triple-agonist profile is of interest in research because it is distinct from single- or dual-receptor analogs. Heavy Kingdom does not claim clinical outcomes for this product.

Laboratory specifications

Catalog name	HK-RT
Compound identity	LY3437943
Type	Triple-agonist incretin analog (GLP-1 / GIP / glucagon)
CAS	2381089-83-2
Molecular formula	C₂₅₆H₃₉₂N₆₄O₇₉
Molecular weight	~4731 Da
Appearance	White to off-white lyophilized powder
Available amounts	10 mg and 30 mg vials
Intended use	Laboratory research only
Storage	Keep frozen, protected from light and moisture, according to your laboratory’s peptide-handling SOP

Published literature

Peer-reviewed papers below are listed so researchers can locate background reading on this analog class. They are not product claims and do not describe Heavy Kingdom lots.

Jastreboff et al., The New England Journal of Medicine (2023). Triple-hormone-receptor agonist — Phase 2 trial. PMID 37366315.
Rosenstock et al., The Lancet (2023). GIP, GLP-1, and glucagon receptor agonist — Phase 2 trial. PMID 37385280.

For laboratory and research use only. Not for human or veterinary consumption. Match any analytical report to the lot printed on your vial before use.

Laboratory handling

Form	Lyophilized powder in a sealed research vial
Lyophilized storage	Keep sealed, desiccated, and protected from light. Typical research storage is −4°F (−20°C) (or −112°F (−80°C) for longer holds). Unopened vials may be held at 36°F–46°F (2°C–8°C) for short periods. Follow your laboratory SOP.
After reconstitution	Typical research handling is refrigeration at 36°F–46°F (2°C–8°C), use within about 30 days, and avoiding repeated freeze–thaw cycles. Warm sealed vials to room temperature before opening.
Documentation	Match any analytical report to the lot printed on the vial. Product photos are not a substitute for a lot-specific report.
Intended use	Laboratory research only. Not for human or veterinary use, consumption, or diagnostic or therapeutic procedures.

Storage guide · Handling guide · How to read a COA